| 1.12 -0.01 (-0.88%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.44  |
1-year : | 1.55 |
| Resists | First : | 1.23 |
Second : | 1.33 |
| Pivot price | 1.19 |
|||
| Supports | First : | 1.08 |
Second : | 0.89 |
| MAs | MA(5) : | 1.16 |
MA(20) : | 1.2 |
| MA(100) : | 1.35 |
MA(250) : | 1.39 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.3 |
D(3) : | 28.5 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GERN ] has closed below the lower bollinger band by 4.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 1.06 - 1.07 | 1.07 - 1.08 |
| Close: | 1.11 - 1.12 | 1.12 - 1.13 |
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Fri, 23 Oct 2026
Geron Corporation Estimates – NASDAQ:GERN - TradingView
Fri, 23 Oct 2026
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 20 Oct 2026
Geron Corporation (1GERN.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 16 Oct 2026
Geron Corporation Rings the Closing Bell - Nasdaq
Fri, 09 Oct 2026
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Tue, 18 Aug 2026
Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 642 (M) |
| Shares Float | 556 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 77 (%) |
| Shares Short | 73,890 (K) |
| Shares Short P.Month | 85,090 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -33.1 % |
| Operating Margin | -22.1 % |
| Return on Assets (ttm) | -4.2 % |
| Return on Equity (ttm) | -28.3 % |
| Qtrly Rev. Growth | 17.2 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -10.19 |
| PEG Ratio | 0 |
| Price to Book value | 3.29 |
| Price to Sales | 3.51 |
| Price to Cash Flow | -6.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|